Captopril
From Proteopedia
(Difference between revisions)
David Canner (Talk | contribs)
(New page: <applet load="" size="480" color="" frame="true" spin="on" Scene ="Rosiglitazone/Rosiglitazon/1" align="right" caption="Rosiglitazone, also known as Avandia"/> ===Better Known as: Capot...)
Next diff →
Revision as of 16:49, 28 November 2010
|
Better Known as: Capoten
- Marketed By: Bristol-Myers Squibb
- Major Indication: Hypertension & Congestive Heart Failure
- Drug Class: ACE Inhibitor
- Date of FDA Approval (Patent Expiration): 1981 (1996)
- 2009 Sales: N/A
- Why You Should Care: It was the first Angiotensin-Converting Enzyme Inhibitor. Was one of the earliest successes of Structure-Based drug design.
- The following is a list of Pharmacokinetic Parameters. See: Pharmaceutical Drugs for more information
Mechanism of Action
Pharmacokinetics
| ACE-Inhibitor Pharmacokinetics Comparison at Equivalent Dosages [1][2][3][4] | |||||
|---|---|---|---|---|---|
| Parameter | Captopril | Lisinopril | Enalapril | Benazepril | |
| Tmax (hr) | |||||
| Cmax (ng/ml) | |||||
| Bioavailability (%) | |||||
| Protein Binding (%) | 96.7 | ||||
| T1/2 (hr) | |||||
| AUC (ng/ml/hr) | |||||
| IC50 (nM) | |||||
| Equivalent Dosage (mg) | |||||
| Metabolism | |||||
